載入...
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
The discovery of activating BRAF mutations in approximately 50% of melanomas has led to the development of MAPK pathway inhibitors, which have transformed melanoma therapy. However, not all BRAF-V600E melanomas respond to MAPK inhibition. Therefore, it is important to understand why tumors with the...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342073/ https://ncbi.nlm.nih.gov/pubmed/27655717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12078 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|